DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w5pdcf/immunotherapy_in) has announced the addition of the "Immunotherapy in Oncology Drug Pipeline Update 2014" report to their offering.
There are today 597 companies plus partners developing 1058 cancer immunotherapy drugs in 2719 developmental projects in cancer. In addition, there are 19 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 498 drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 433 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 398 out of the 403 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 68 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 597 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 1058 cancer immunotherapy drugs in development, which have a total of 2719 developmental projects in cancer. In addition there are suspended and ceased drugs.
Included cancer immunotherapy drugs are also in development for 278 other indications, where of 148 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
- Marketed # 74
- Registered # 1
- Pre-registration # 9
- Phase III # 104
- Phase II # 306
- Phase I # 316
- Preclinical # 607
- No Data # 11
- Suspended # 19
- Ceased # 498
For more information visit http://www.researchandmarkets.com/research/w5pdcf/immunotherapy_in